Defendant
1 case as defendant.
Optum, Inc., commonly known as Optum, is an American healthcare company founded in 2011 and headquartered in Eden Prairie, Minnesota. It operates as a subsidiary of UnitedHealth Group (NYSE: UNH). Optum is a large-scale enterprise, employing approximately 300,000 people worldwide. Its revenue surpassed $100 billion in 2019, with projected revenues between $212 billion and $214 billion for 2023 and an estimated $270.6 billion for 2025.
The company provides a wide array of healthcare services, delivered through three primary business segments: OptumHealth, OptumInsight, and OptumRx. OptumHealth focuses on direct care delivery, population health management, and health financial services, including primary, specialty, and urgent care. OptumInsight offers data, analytics, and technology solutions to hospitals, health plans, and life sciences companies to streamline administrative and financial processes. OptumRx functions as a major pharmacy benefit manager, providing pharmacy care services, specialty pharmacy, and infusion therapies. Optum serves various clients including employers, government agencies, health plans, care providers, and individuals.
Optum's patent litigation posture, based on available data, identifies it as an operating company defending against legal challenges. The company has been involved in one tracked case as a defendant and zero as a plaintiff. This profile is consistent with an entity that provides products and services and is subject to litigation from other parties.
The single tracked case, Parallax Behavioral Health, Inc. v. Optum, Inc., was filed on February 10, 2023, in the Delaware District Court. This case involves Optum as a defendant. Parallax Behavioral Health, Inc. may be related to Parallax Health Sciences Inc., which faced SEC charges in 2021 for misleading statements regarding COVID-19 products and services. Optum's subsidiary, United Behavioral Health, has previously been involved in class-action lawsuits concerning mental health and substance use disorder claims.
Parallax Behavioral Health, Inc. sued Optum, Inc. for patent infringement of US patent 11809431. The case is active, and Optum's motion to stay discovery pending IPR was denied on May 17, 2024.